Search Results
Your search for ,WHo matches 20206 pages
Showing 6401 - 6450Eric P. Winer, MD, FASCO, Elected ASCO President for 2022–2023 Term
ASCO has elected Eric P. Winer, MD, FASCO, a longtime member and volunteer, to serve as its President for the term beginning in June 2022. He will take office as President-Elect during the ASCO Annual Meeting in June 2021. Five new members were also elected to the ASCO Board of Directors and the...
FDA Authorizes Antigen Test as First Over-the-Counter, Fully At-Home Diagnostic Test for COVID-19
On December 15, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the first over-the-counter, fully at-home diagnostic test for COVID-19. The Ellume COVID-19 Home Test is a rapid, lateral-flow antigen test, a type of test that runs a liquid sample along a...
Postoperative Cancer Surgery Mortality Rates Have Improved, but Gap Still Exists Between Black and White Patients
Mortality rates after cancer surgery declined for Black as well as White patients during a recent 10-year period, although the mortality gap between the two groups did not narrow, according to new research published by Miranda Lam, MD, MBA, and colleagues in JAMA Network Open. The findings present...
ASH 2020: ctDNA May Indicate Increased Risk of Relapse After Stem Cell Transplant in Patients With DLBCL
Many patients with diffuse large B-cell lymphoma (DLBCL) may be cured by autologous stem cell transplant, but as many as half eventually relapse. New research presented by Reid Merryman, MD, and colleagues at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition suggests...
ESMO Immuno-Oncology 2020: Does Pleural Effusion Affect Survival in Patients Treated With Immunotherapy for NSCLC?
Patients with non–small cell lung cancer (NSCLC) who have pleural effusion, especially those requiring pleural evacuation, experienced poorer survival when treated with immune checkpoint inhibitors, according to findings presented by Epaillard et al at the European Society for Medical Oncology...
SABCS 2020: CTC Enumeration May Be Predictive of Survival During Treatment for Metastatic Breast Cancer
The number of circulating tumor cells (CTCs) assessed at baseline and about 1 month after cancer-directed treatment was associated with overall survival in patients with metastatic breast cancer, according to findings from a large retrospective pooled analysis reported by Wolfgang Janni, MD, PhD,...
SABCS 2020: Patient-Reported Outcomes From the Phase III IMpassion031 Trial
Adding an immune checkpoint inhibitor to a standard chemotherapy regimen for patients with early-stage triple-negative breast cancer did not affect patients’ ability to perform day-to-day activities more than treatment with chemotherapy alone, according to research presented by Elizabeth...
SABCS 2020: New Prognostic Tool to Determine Individual Risk of Distant Recurrence, Benefit of Adjuvant Chemotherapy in Early Breast Cancer
In a study presented at the 2020 San Antonio Breast Cancer Symposium (Abstract GS4-10) and concurrently published in the Journal of Clinical Oncology, Joseph A. Sparano, MD, and colleagues described the development and validation of a new prognostic tool. RSClin integrates the 21-gene recurrence...
FDA Issues Emergency Use Authorization for First COVID-19 Vaccine
On December 11, the U.S. Food and Drug Administration (FDA) issued the first emergency use authorization (EUA) for a vaccine for the prevention of COVID-19 caused by SARS-CoV-2 in individuals aged 16 and older. The EUA allows the Pfizer-BioNTech COVID-19 vaccine to be distributed in the United...
SABCS 2020: RxPONDER Study Shows Postmenopausal Patients With Node-Positive Breast Cancer May Be Able to Avoid Chemotherapy
Just in are the results of the SWOG S1007 RxPONDER trial, which evaluated the benefit of chemotherapy in women with early-stage, hormone receptor (HR)-positive, node-positive breast cancer. Based on the findings, many postmenopausal women may be able to safely skip adjuvant chemotherapy. However,...
ASH 2020: Phase II ZUMA-12 Study Investigates Axicabtagene Ciloleucel for High-Risk Large B-Cell Lymphoma
The phase II ZUMA-12 trial found that axicabtagene ciloleucel, an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, is a safe and effective therapy for patients with high-risk large B-cell lymphoma. These results were presented by Sattva S. Neelapu, MD, and colleagues at the 2020 ...
SABCS 2020: Follow-up Data From monarchE Show Continued Abemaciclib Benefit in High-Risk, HR-Positive, HER2-Negative Breast Cancer
Extended follow-up results from the phase III monarchE trial showed that adding the cyclin-dependent kinase inhibitor abemaciclib to standard adjuvant endocrine therapy continued to improve invasive disease–free survival in patients with high-risk, node-positive, early-stage, hormone receptor...
SABCS 2020: Can Mindfulness Meditation and Survivorship Education Help to Reduce Depression in Young Breast Cancer Survivors?
New research showed that behavioral interventions—mindfulness meditation and survivorship education classes—may be effective in reducing depressive symptoms in younger breast cancer survivors. This patient population often experiences the highest levels of depression, stress, and fatigue, which may ...
Debra A. Pratt, MD, on Time to Completion of Breast Cancer Treatment and Survival
In her recent study, Debra A. Pratt, MD, of the Cleveland Clinic, showed that when breast cancer treatment using any of three modalities takes longer than 38 weeks, it is associated with a decrease in survival, regardless of the receptor status. Patients with breast cancer who received neoadjuvant...
SITC Announces Creation of Steven A. Rosenberg, MD, PhD, Endowed Scholars Fund
The Society for Immunotherapy of Cancer (SITC) has announced the creation of the Steven A. Rosenberg, MD, PhD, Endowed Scholars Fund. Established in honor of Dr. Rosenberg, this fund recognizes his many contributions to the field by supporting investigators who are emerging leaders in...
Sara Federico, MD, Receives NCI Award for Leadership in Developing Clinical Trials for Pediatric Cancer
Sara Federico, MD, associate member of the Department of Oncology at St. Jude Children’s Research Hospital, has received the 2020 Cancer Clinical Investigator Team Leadership Award from the National Cancer Institute (NCI). This award recognizes and supports outstanding mid-career clinical...
2020 William Dameshek Prize Awarded to Adolfo Ferrando, MD, PhD
The American Society of Hematology (ASH) presented the 2020 William Dameshek Prize to Adolfo Ferrando, MD, PhD, of Columbia University Institute for Cancer Genetics in New York, for his outstanding research on the impact of NOTCH1 mutations on T-cell acute lymphoblastic leukemia (ALL). “I am...
New Rules on Health-Care Price Transparency and Coverage for COVID-19 Vaccines
ON OCTOBER 28, the U.S. Department of Health and Human Services (HHS), the U.S. Department of Labor, and the U.S. Department of the Treasury released the coverage transparency final rule. Building on earlier administration actions requiring hospitals to disclose standard charges and negotiated...
Albert Einstein College of Medicine Researchers Receive $5 Million Grant From the National Institutes of Health
A TEAM OF SCIENTISTS from Albert Einstein College of Medicine has received a 5-year, $4.9 million grant from the National Institutes of Health (NIH) to establish a research center to investigate human immunodeficiency virus (HIV)- and human papillomavirus (HPV)-related cancers in Africa. The...
City of Hope Orange County Names Edward S. Kim, MD, MBA, Its Physician-in-Chief
CITY OF HOPE ORANGE COUNTY recently announced the appointment of cancer researcher and clinician Edward S. Kim, MD, MBA, as Senior Vice President and Vice Physician-in-Chief at City of Hope and Orange County Physician-in-Chief. “Dr. Kim has a depth and breadth of cancer expertise that is well...
World Health Organization Launches First-Ever Global Commitment to Eliminate Cervical Cancer
THE WORLD HEALTH ORGANIZATION (WHO) has launched the Global Strategy to Accelerate the Elimination of Cervical Cancer, outlining three key steps: vaccination, screening, and treatment. Successful implementation of all three could reduce more than 40% of new cases of the disease and 5 million...
Career Development Award Winner Dr. Aparna Parikh on the Emerging Importance of Liquid Biopsies for GI Cancers
Systematic liquid biopsies are transforming treatment approaches for patients with gastrointestinal (GI) cancers. Many GI tumors are detected late, which ultimately reduces 5-year overall survival rates. Liquid biopsies may become increasingly important both in the early detection and treatment...
ASCO Announces Julie R. Gralow, MD, FACP, FASCO, as New Chief Medical Officer
Julie R. Gralow, MD, FACP, FASCO, Professor of Medical Oncology and Director of Breast Medical Oncology at the University of Washington, Fred Hutchinson Cancer Research Center, and the Seattle Cancer Care Alliance, has been named the next Chief Medical Officer of ASCO. Dr. Gralow will succeed...
Staying a Step Ahead of Cancer
When I was diagnosed with metastatic breast cancer in 2018, my first thought was, I hope my three young children do not lose two parents to cancer. My husband, Ricky, had survived two bouts of cancer, early-stage colorectal cancer and, most recently, stage I kidney cancer. Like Ricky’s two...
Project Orbis: Partnering With International Regulatory Agencies to Bring Earlier Global Access to Novel Cancer Treatments
OCE Insights is an occasional department developed for The ASCO Post by members of the Oncology Center of Excellence (OCE) at the U.S. Food and Drug Administration (FDA). In this installment, Preeti Narayan, MD, a medical oncologist and clinical reviewer on the Breast and Gynecologic Disease Team,...
Continued Progression-Free and Overall Survival Superiority of First-Line Pembrolizumab/Axitinib vs Sunitinib
As reported in The Lancet Oncology by Thomas Powles, MD, of Barts Cancer Institute, London, and colleagues, extended follow-up of the phase III KEYNOTE-426 trial shows continued progression-free and overall survival superiority with pembrolizumab/axitinib vs sunitinib alone in first-line treatment ...
Improved Outcomes With Neoadjuvant Paclitaxel Plus Trastuzumab/Lapatinib vs Paclitaxel/Trastuzumab in HER2-Positive Breast Cancer
In a 7-year follow-up of the phase III CALGB 40601/Alliance trial reported in the Journal of Clinical Oncology, Aranzazu Fernandez-Martinez, MD, of Lineberger Comprehensive Center, University of North Carolina, Chapel Hill, and colleagues found that neoadjuvant paclitaxel combined with a dual...
ASCO Releases Guideline on Systemic Therapy for Advanced Hepatocellular Carcinoma
ASCO has released a new evidence-based clinical practice guideline to assist in clinical decision-making for patients with advanced hepatocellular carcinoma.1 “Advanced hepatocellular carcinoma has transitioned from a disease where we had a single approved therapy for patients to one where we now...
Bristol Myers Squibb Foundation and National Medical Fellowships Launch Program to Increase Diversity in Clinical Trials
The Bristol Myers Squibb Foundation and National Medical Fellowships recently announced their new partnership, which is aimed at improving diversity in clinical trials. Leveraging $100 million of the previously announced commitment to diversity and inclusion from Bristol Myers Squibb and the...
What Is the Measure of Minimal Residual Disease in AML?
Relapse is the primary obstacle to cure in leukemia. The term minimal residual disease (MRD) was coined in the early 1990s to describe finding a disease-specific marker in the context of a morphologic-appearing remission. The technique first used for MRD detection was the Southern blot (!), but the ...
Facing Life’s Adversities, Even Cancer, From the Back of a Horse Named Buddy
“A bald eagle skims along the bluff where windblown Douglas firs, their exposed roots like talons, grip the eroding cliffs. Gulls circle and warn the bird of prey not to get too close. One hundred fifty feet below, the Salish Sea crashes and stretches west to the Pacific.” So begins Wild Ride Home: ...
Edward J. Benz, Jr, MD, Receives 2020 ASH Award for Leadership in Promoting Diversity
The 2020 American Society of Hematology (ASH) Award for Leadership in Promoting Diversity was awarded to Edward J. Benz, Jr, MD, President and Chief Executive Officer Emeritus of the Dana-Farber Cancer Institute and the Richard and Susan Smith Distinguished Professor at Harvard Medical School. Dr....
The Lung Microbiome May Affect Lung Cancer Pathogenesis and Prognosis
Enrichment of the lungs with oral commensal microbes was associated with advanced-stage disease, worse prognosis, and tumor progression in patients with lung cancer, according to results from a study published in Cancer Discovery, a journal of the American Association for Cancer Research.1 “The...
Progress Report on Checkpoint Inhibitors in Rare Tumors
Immune checkpoint inhibitors may prove to be effective in treating patients with two rare cancer types—leptomeningeal metastases and angiosarcoma, according to early-phase clinical trials reported at the 2020 Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which was held virtually ...
Immunotherapy for Triple-Negative Breast Cancer: An Evolving Story
Immunotherapy with checkpoint inhibitors, established as a treatment of many solid tumors, may be finding a role in the treatment of breast cancer. The current state of the art regarding immunotherapy for triple-negative breast cancer was the focus of a talk by Heather L. McArthur, MD, MPH, Medical ...
Emerging Data on PARP Inhibition in Prostate Cancer
Prostate cancer has lagged behind other solid tumors with regard to molecularly targeted therapy and precision medicine, with no targeted therapies approved specifically in prostate cancer, but that has changed with the recent approval in 2020 of a PARP (poly [ADP-ribose] polymerase) inhibitor for...
Understanding Breast Cancer Diagnosis and Treatment Disparities in Resource-Challenged Nations
Cancer is the second leading cause of death in the Caribbean. Adding to this growing burden, many of the nations in this geographically spread region have under-resourced health-care systems and a lack of cohesive approaches to the delivery of cancer care. To shed light on the public health...
ASH Recognizes Admiral Brett Giroir, MD, With 2020 Outstanding Service Award
The American Society of Hematology (ASH) honored Admiral Brett Giroir, MD, Assistant Secretary for Health at the U.S. Department of Health and Human Services (HHS), for his outstanding support of hematology research and patient care. At the all-virtual annual meeting, Admiral Giroir received the...
Hannah Hazard-Jenkins, MD, Named Permanent Director of the WVU Cancer Institute
Hannah Hazard-Jenkins, MD, Associate Chair of Surgery for Cancer Services, has been named permanent Director of the West Virginia University (WVU) Cancer Institute after having served in the position on an interim basis since January. “As a native West Virginian, it is my honor to serve in this...
Expert Point of View: Joel W. Neal, MD, PhD
Invited discussant of the abstract, Joel W. Neal, MD, PhD, Associate Professor of Medicine at Stanford University, called this real-world analysis novel,1 given the decreasing number of patients treated with single-agent immunotherapy. “I think we’re unlikely to have a larger prospective study [in...
Lung Cancer Progression-Free Survival With Immunotherapy Varies Significantly by Tumor-Mutation Subtype, Real-World Data Show
A real-world study of single-agent immune checkpoint inhibitors in driver-mutated non–small cell lung cancer (NSCLC) has demonstrated significant variation in progression-free survival between mutation subtypes, according to data presented during the International Association for the Study of Lung...
Daniel D. Von Hoff, MD, FACP, FASCO, FAACR, Receives Inaugural AACR Scientific Achievement Award Established in His Honor
The American Association for Cancer Research (AACR) recently announced that Daniel D. Von Hoff, MD, FACP, FASCO, FAACR, will receive the inaugural AACR Daniel D. Von Hoff Award for Outstanding Contributions to Education and Training in Cancer Research. Dr. Von Hoff is being recognized for his...
Early-Stage Lung Cancer: An Overview of the Clinical Trial Landscape
Although early-stage, resectable disease represents the best chance for meaningful long-term survival and cure for patients with lung cancer, there are still high rates of recurrence. According to Rajwanth Veluswamy, MD, MSCR, neoadjuvant and adjuvant treatments are needed to improve surgical...
Expert Point of View: Ramesh Rengan, MD, PhD
Formal discussant of this trial, Ramesh Rengan, MD, PhD, Professor and Chair, Department of Radiation Oncology, University of Washington, and Professor, Fred Hutchinson Cancer Research Center, Seattle, commented: “My interpretation in the follow-up period is that low-dose radiation therapy is...
Low-Dose Radiotherapy for COVID-19–Related Pneumonia
Whole-lung low-dose radiation therapy led to quicker recovery from COVID-19–related pneumonia in hospitalized and oxygen-dependent patients compared with matched controls treated with best supportive care and physician’s choice of anti–COVID-19 therapy, according to the results of a small trial.1...
Expert Point of View: Matthijs Oudkerk, MD
Matthijs Oudkerk, MD, Professor of Radiology at the University Medical Center Groningen, Netherlands, and Principal Investigator for Radiology of the NELSON Lung Cancer Detection Study, stressed that detecting individuals who have early-stage lung cancer with more virulent biologic behavior is...
Geriatric Assessment: Vital Element in Individualizing Care for Older Patients With Cancer
Caring for older adults with cancer is the purview of every oncologist. Over the next 30 years, the older adult population (65 years and older) will represent the fastest-growing segment of the world population. Globally, the number of persons 80 years and older is expected to triple from 143...
FDA and AACR Launch Project Livin’ Label
The American Association for Cancer Research (AACR) and the U.S. Food and Drug Administration (FDA) will collaborate on Project Livin’ Label, a new educational initiative that aims to foster broad understanding of specific oncology product labels and increase awareness of recent oncology drug FDA...
Living Well Before We Die
Editor’s Note: The following essay was first published in 2011. It is being reprinted here with permission from the author and publisher. In 2020, the American Academy of Hospice and Palliative Medicine (AAHPM) now includes more than 5,000 members; the annual meeting convenes more than 3,200...
Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Colombia
Colombia is located in the northwestern corner of South America, geographically privileged with coasts on both the Atlantic and Pacific Oceans, the Andean region, and the Amazon rainforest. Based on its population of nearly 50 million (see Table 1), Colombia is the second largest country in South...
